Genetic susceptibility to symptomatic norovirus infection in Nicaragua.
Host genetic resistance to Norovirus (NoV) has been observed in challenge and outbreak studies in populations from Europe, Asia, and USA. In this study, we have investigated if histo-blood group antigens can predict susceptibility to diarrhea caused by NoV in Nicaragua, Central America, and if this can be reflected in antibody-prevalence and titer to NoV among individuals with different histo-blood group antigen phenotypes. Investigation of 28 individuals infected with NoV and 131 population controls revealed 6% of non-secretors in the population and nil non-secretors among patients infected with NoV, suggesting that non-secretors may be protected against NoV disease in Nicaragua. Surprisingly, 25% of the population was Lewis negative (Le(a-b-)). NoV infections with genogroup I (GI) and GII occurred irrespective of Lewis genotype, but none of the Lewis a positive (Le(a + b-)) were infected. The globally dominating GII.4 virus infected individuals of all blood groups except AB (n = 5), while the GI viruses (n = 4) infected only blood type O individuals. Furthermore, O blood types were susceptible to infections with GI.4, GII.4, GII.7, GII.17, and GII.18-Nica viruses, suggesting that secretors with blood type O are susceptible (OR = 1.52) and non-secretors resistant. The overall antibody-prevalence to NoV GII.3 VLP was 62% with the highest prevalence among blood type B carriers (70%) followed by A (68%) and O (62%). All four investigated individuals carrying blood type AB were antibody-negative. Among secretors, 63% were antibody-positive compared to 33% among non-secretors (P = 0.151). This study extends previous knowledge about the histo-blood group antigens role in NoV disease in a population with different genetic background than North American and European.
Bucardo
Filemon
F
Department of Microbiology, University of León, Nicaragua (UNAN-León).
Kindberg
Elin
E
Paniagua
Margarita
M
Grahn
Ammi
A
Larson
Göran
G
Vildevall
Malin
M
Svensson
Lennart
L
D000017:ABO Blood-Group System; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D001789:Blood Group Antigens; D017250:Caliciviridae Infections / Q000453:epidemiology / Q000235:genetics* / Q000503:physiopathology / Q000821:virology; D002648:Child; D002675:Child, Preschool; D018389:Codon, Nonsense; D005647:Fucosyltransferases / Q000235:genetics; D005759:Gastroenteritis / Q000453:epidemiology / Q000235:genetics* / Q000503:physiopathology / Q000821:virology; D020022:Genetic Predisposition to Disease; D006801:Humans; D007223:Infant; D007983:Lewis Blood Group Antigens; D008875:Middle Aged; D009527:Nicaragua / Q000453:epidemiology; D029322:Norovirus / Q000145:classification / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity*; D015995:Prevalence; D055815:Young Adult; D000097631:Galactoside 2-alpha-L-fucosyltransferase
D000017:ABO Blood-Group System; D000914:Antibodies, Viral; D001789:Blood Group Antigens; D018389:Codon, Nonsense; D005647:Fucosyltransferases; D007983:Lewis Blood Group Antigens; D000097631:Galactoside 2-alpha-L-fucosyltransferase